- Home
- PRQR vs VSTM Comparison
PRQR vs VSTM Comparison
Compare PRQR & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- VSTM
- Stock Information
- Founded
- PRQR 2012
- VSTM 2010
- Country
- PRQR Netherlands
- VSTM United States
- Employees
- PRQR N/A
- VSTM N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- VSTM Health Care
- Exchange
- PRQR Nasdaq
- VSTM Nasdaq
- Market Cap
- PRQR 309.5M
- VSTM 313.1M
- IPO Year
- PRQR 2014
- VSTM 2012
- Fundamental
- Price
- PRQR $1.37
- VSTM $5.84
- Analyst Decision
- PRQR Strong Buy
- VSTM Strong Buy
- Analyst Count
- PRQR 6
- VSTM 8
- Target Price
- PRQR $8.50
- VSTM $13.00
- AVG Volume (30 Days)
- PRQR 723.0K
- VSTM 930.9K
- Earning Date
- PRQR 03-13-2025
- VSTM 03-20-2025
- Dividend Yield
- PRQR N/A
- VSTM N/A
- EPS Growth
- PRQR N/A
- VSTM N/A
- EPS
- PRQR N/A
- VSTM N/A
- Revenue
- PRQR $20,235,014.00
- VSTM $10,000,000.00
- Revenue This Year
- PRQR $39.44
- VSTM N/A
- Revenue Next Year
- PRQR N/A
- VSTM $867.23
- P/E Ratio
- PRQR N/A
- VSTM N/A
- Revenue Growth
- PRQR 196.41
- VSTM N/A
- 52 Week Low
- PRQR $1.25
- VSTM $2.10
- 52 Week High
- PRQR $4.62
- VSTM $13.52
- Technical
- Relative Strength Index (RSI)
- PRQR 25.70
- VSTM 41.38
- Support Level
- PRQR $1.25
- VSTM $5.68
- Resistance Level
- PRQR $1.87
- VSTM $6.33
- Average True Range (ATR)
- PRQR 0.09
- VSTM 0.50
- MACD
- PRQR -0.02
- VSTM -0.16
- Stochastic Oscillator
- PRQR 21.43
- VSTM 18.62
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.